Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

McKesson
Mallinckrodt
Baxter
AstraZeneca
Moodys
Merck

Last Updated: November 17, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR RITALIN

See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Ritalin

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00018863 Treatment of Attention Deficit Hyperactivity Disorder in Preschool-Age Children (PATS) Unknown status National Institute of Mental Health (NIMH) Phase 3 2001-04-01 This research focuses on the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in very young children. The medication being used is methylphenidate (Ritalin); it is being studied to determine its safety and how well it works to treat ADHD in preschool-age children (3-5.5 year olds).
NCT00018863 Treatment of Attention Deficit Hyperactivity Disorder in Preschool-Age Children (PATS) Unknown status New York State Psychiatric Institute Phase 3 2001-04-01 This research focuses on the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in very young children. The medication being used is methylphenidate (Ritalin); it is being studied to determine its safety and how well it works to treat ADHD in preschool-age children (3-5.5 year olds).
NCT00025779 Methylphenidate in Children and Adolescents With Pervasive Developmental Disorders Completed National Institute of Mental Health (NIMH) N/A 2001-10-01 This study will evaluate the efficacy and safety of methylphenidate for treating hyperactivity, impulsiveness, and distractibility in 60 children and adolescents with Pervasive Developmental Disorders (PDD). Methylphenidate (Ritalin)is approved by the Food and Drug Administration for the treatment of children and adolescents with Attention Deficit Hyperactivity Disorder (ADHD). Data supporting its safety and effectiveness in treating ADHD symptoms in PDD are limited. Children and adolescents who do not show a positive response to methylphenidate will be invited to participate in a pilot study of the non-stimulant medication guanfacine (Tenex).
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Ritalin

Condition Name

Condition Name for Ritalin
Intervention Trials
Attention Deficit Hyperactivity Disorder 21
Healthy 9
Attention Deficit Disorder With Hyperactivity 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Ritalin
Intervention Trials
Attention Deficit Disorder with Hyperactivity 38
Hyperkinesis 29
Disease 21
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Ritalin

Trials by Country

Trials by Country for Ritalin
Location Trials
United States 91
Israel 16
Canada 9
Netherlands 4
Switzerland 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Ritalin
Location Trials
California 12
Texas 9
Massachusetts 8
Ohio 7
New York 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Ritalin

Clinical Trial Phase

Clinical Trial Phase for Ritalin
Clinical Trial Phase Trials
Phase 4 28
Phase 3 14
Phase 2/Phase 3 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Ritalin
Clinical Trial Phase Trials
Completed 46
Recruiting 18
Unknown status 17
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Ritalin

Sponsor Name

Sponsor Name for Ritalin
Sponsor Trials
Massachusetts General Hospital 8
National Institute of Mental Health (NIMH) 7
Shalvata Mental Health Center 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Ritalin
Sponsor Trials
Other 127
NIH 19
Industry 13
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Baxter
Moodys
Merck
McKinsey
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.